Showing 2081-2090 of 7783 results for "".
Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execPsoriasis Comorbidities: Assessing Risks and the Role of Dermatologists
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities-assessing-risks-and-the-role-of-dermatologists-/18242/Ronald Prussick, MD discusses the most common comorbidities of psoriasis and the risks patients have for cardiovascular issues, depression, fatty liver disease, vitamin D deficiency, and more. He talks to host Nancy Samolitis, MD about the role dermatologists play in assessing and treating these risBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.A Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.Inclusivity: A Concerted Effort
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/inclusivity-a-concerted-effort/19915/Historical events and recent developments contribute to some patients’ skepticism of medicine in general and dermatology specifically. Hear what panelists say about the best approaches to expand inclusivity in research, clinical trials, and patient care. It will take a concerted effort to overcome cQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do not